Literature DB >> 31243199

Herpes Zoster Laryngitis with Disseminated Cutaneous Lesions.

Hirokazu Kuroda1,2, Ryota Hase2.   

Abstract

Entities:  

Keywords:  herpes zoster; laryngitis; varicella-zoster virus

Year:  2019        PMID: 31243199      PMCID: PMC6815882          DOI: 10.2169/internalmedicine.2886-19

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


× No keyword cloud information.
An 85-year-old man with malignant lymphoma presented with a 3-day history of right-sided progressive sore throat and odynophagia. He had received rituximab three weeks before this presentation. A physical examination revealed no abnormality in the oral cavity or pharynx. Flexible laryngoscopy revealed multiple whitish mucosal lesions on the right side of the epiglottis and larynx (Picture 1). Suspecting varicella-zoster virus (VZV) infection, the intravenous administration of acyclovir was initiated. On day 4 of admission, the patient developed erythematous papules and vesicles throughout the body (Picture 2), indicating disseminated VZV infection. A polymerase chain reaction analysis of the skin lesions revealed positivity for VZV, establishing active VZV infection. The patient completely recovered after 10-day antiviral therapy. Herpes zoster laryngitis, a rare presentation of VZV infection, manifests as unilateral painful mucosal lesions on the larynx (1) and requires specific antiviral treatment and infection control, especially in patients with disseminated lesions. Therefore, the appropriate diagnosis is essential, and VZV infection should be considered in patients, particularly elderly people and immunocompromised hosts, with unilateral sore throat and odynophagia.
Picture 1.
Picture 2.
The authors state that they have no Conflict of Interest (COI).
  1 in total

Review 1.  Viral laryngitis: a mimic and a monster - range, presentation, management.

Authors:  Laura M Dominguez; C Blake Simpson
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2015-12       Impact factor: 2.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.